REGN1033 vs ACE-031
Head-to-head comparison of REGN1033 (Trevogrumab (REGN1033)) and ACE-031 (ACE-031 (soluble activin receptor type IIB-Fc)) — benefits, dosing, side effects, research data, and where to buy.
| Property | REGN1033 | ACE-031 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Trevogrumab (REGN1033) | ACE-031 (soluble activin receptor type IIB-Fc) |
| Molecular Weight | ~150 kDa | ~95 kDa |
| Half-Life | ~2-3 weeks | Days to weeks |
| Amino Acids | N/A | N/A |
| Typical Dose | 100-300 mg SC or equivalent trial dosing | 0.1-3 mg/kg in early studies |
| Route | Subcutaneous / Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 60 | 75 |
| Research Status | Clinical | Clinical |
REGN1033 Benefits
- ✓myostatin blockade
- ✓lean-mass preservation
- ✓muscle hypertrophy support
- ✓catabolic-state countermeasure
ACE-031 Benefits
- ✓myostatin/activin neutralization
- ✓lean mass gain
- ✓muscle function support
- ✓anti-catabolic effect
REGN1033 Dosing
SC or IV clinical-trial dosing|repeat every 2-4 weeks|dose escalation by study
ACE-031 Dosing
Clinical studies used single or repeated SC doses|dose escalation in mg/kg|monitoring for edema/bleeding
REGN1033 Side Effects
- ⚠injection-site reactions
- ⚠headache
- ⚠fatigue
ACE-031 Side Effects
- ⚠telangiectasia/vascular effects
- ⚠epistaxis
- ⚠headache/edema
Research Overview
REGN1033
Human and animal studies indicate that myostatin neutralization can increase muscle size, though functional gains are often smaller than mass gains. Trevogrumab is part of the broader literature showing that selective myostatin inhibition can alter body composition in clinically meaningful ways.
ACE-031
ACE-031 produced increases in lean mass in early studies, but development was curtailed after safety concerns and variable efficacy. Its literature remains important because it validated activin receptor blockade as a muscle-building strategy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.